Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 1,001–1,100 of 1,139
Neue Therapieansätze bei MASH: Mechanismen und klinisches Potenzial
Barton, A., & Schattenberg, J. M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2894-7716
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Moiz, A., Reynier, P., Tsoukas, M. A., Yu, O. H., Peters, T. M., Eisenberg, M. J., & Filion, K. B. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03153-6
“More recently, the phase 2 trial of the triple-agonist retatrutide reported up to 22.1% weight loss at 48 weeks [12].”
InfluentialDiabesity Treatments Today and Tomorrow
Pavlakis, G., & Goldman, J. D. (2023) · ADCES in Practice · doi:10.1177/2633559x231202497
Genetische Ursachen der Adipositas und ihre therapeutischen Implikationen
Rajcsanyi, L. S., Schmidt, J., Düerkop, S., Grote, L., Peters, T., Körner, A., Fischer‐Posovszky, P., & Hinney, A. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2185-6864
“Auch bei Retatrutide kam es vermehrt zu gastroin-187 Review testinalen Problemen und einer erhöhten Herzfrequenz, die jedoch nach 24 Wochen der Behandlung abnahm [68].”
BackgroundTwin- und Trinkretine: Balanceakt zwischen Diabetes und Adipositas?
Stirban, O. A. (2024) · Info Diabetologie · doi:10.1007/s15034-023-4900-z
Skvortsov, V. V., Skvortsova, E. M., & Makhnach, D. A. (2026) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2605-04
Stewart, K. D., Matza, L. S., Chinthammit, C., Pavo, I. J., Bartee, A. K., & Boye, K. S. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01907-y
Zhou, Q., & Shen, Y. (2026) · Clinical Proteomics · doi:10.1186/s12014-026-09583-7
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
“Cryo-EM data establish that a single peptide can engage both receptors with appropriate conformational selectivity (42), and next-generation multi-receptor agents extend the principle to the glucagon receptor, adding an energy-expenditure component (38, 48, 49).”
InfluentialUpcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice
Newsome, P. N., & Ajaz, S. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70143 · Cited by 2
“Retatrutide has shown in Phase 2 studies for obesity unparalleled weight loss (24% at 48 weeks in obesity trial) and, notably, marked reductions in liver fat (MRI-PDFF ↓ 60%–80% depending on dose) [44].”
TRENDS IN OBESITY TREATMENT: A REVIEW OF THE LITERATURE FROM THE LAST SIX YEARS
Sobiński, A., Sadowska, A., Welkier, A., Miśkiewicz, J., Dudek, A., Pietrusińska, P., Moder, J., Dziewierz, A., Kwaśniewska, P., & Śliwa-Tytko, P. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4326
Obesity and Cardiovascular Diseases: CVIA State-of-the-Art Review
Liu, N., Pan, Y., Liu, F., Mei, J., Zhang, X., Zhang, R., Zhang, S., Luo, F., Wu, Y., Gong, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0010
Self-citationEinfluss von GLP-1-Analoga auf die Mikronährstoffversorgung
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Ernährung & Medizin · doi:10.1055/a-2492-9615
“Tirzepatid und vor allem Retatrutid (Agonist, der an Re - zeptoren von GLP-1, GIP und Glucagon bindet und diese aktiviert) führen zu deutlich höheren Gewichtsverlusten von bis zu 25 % [5, 17, 18].”
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.06.013
Kim, T., Seo, J., Kang, S., Kim, H. K., Lee, B., Lee, J., & Go, G. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02259-w
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.09.003 · Cited by 1
Signal Transduction in Pituitary Functions
Yoshida, D., & Teramoto, A. (2024) · Physiology · doi:10.5772/intechopen.115042
Alkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
“Their place in cardiometabolic care will depend not only on weight reduction but also on cardiovascular and kidney outcomes, long-term safety, treatment persistence, and access [ 78 , 79 ].”
Advances in peptide-based drug discovery
Khatri, B., Velloso, J. P. L., Shambhawi, Kan, M., & Craik, D. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00041-8
Fouad, Y. M., Abdelghany, W. A., & Sheemy, R. Y. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.118303
Medikamentöse Therapie der Adipositas bei Kindern und Jugendlichen
Lischka, J., Torbahn, G., Mörwald, K., Gomahr, J., Jabbour, J., Geiersberger, S., & Weghuber, D. (2025) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-025-02149-1 · Cited by 1
Sun, R., Ronxhi, J., Yang, X., Qian, M. G., & Zhang, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4935710
Incretin analogues as cardiovascular agents: a state-of-the-art review
Garaygordobil, D. A., Rico-Fontalvo, J. E., Hernández-Balbuena, B., Vinay, M., & Gonzalez-Arias, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1898812 · Cited by 1
Carneiro, G. R. A., Nunes, I. K. D. C., dos Santos, G. R. C., dos Santos, P. F., Padilha, M. C., Nogueira, F. C. S., & Pereira, H. M. G. (2026) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.70179
“This interaction is known to reduce renal filtration and slow proteolytic degradation, thereby extending systemic half-life and delaying elimination, a strategy commonly employed in long-acting peptide analogs [6, 26].”
InfluentialMihălțan, F.-D., Borcea, C.-I., & Constantin, A. A. (2026) · Life · doi:10.3390/life16050802
“In addition, the potential use of emerging agents, such as oral nonpeptide GLP-1 receptor agonists (e.g., orforglipron), to maintain weight loss following tirzepatide therapy warrants investigation [95,96].”
Diabetes and Obesity as Catalysts in MASH Progression: Mechanisms and Emerging Therapies
Munda, B., Bhutia, C., Deepti, & Khatri, M. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs151.011
Mandarim‐de‐Lacerda, C. A., & Spezani, R. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.04.020
Use of Pharmacotherapy in Obesity Management
Wei, T. K. (2024) · The Singapore Family Physician · doi:10.33591/sfp.49.9.u5
Wu, J., Zheng, W., Qi, Q., He, C., Zhai, C., & Fan, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51234 · Cited by 1
Pharmacological and Surgical Interventions That Prevent or Remit Type 2 Diabetes
Neeland, I. J., & Baskin, R. L. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00004-5
14. The Cutting Edge of the Treatment of Type 2 Diabetes
Ogawa, W. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.1740
Moiz, A., Filion, K. B., Samuels, A. E., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05519
Neff, K. M. H., Dunford, A., Goldschmidt, A. B., Allison, K. C., & Richeson, A. L. (2026) · International Journal of Eating Disorders · doi:10.1002/eat.70180 · Cited by 1
Browning, T. E., Coy, A., Sehgal, V., Singh, S., Jakhar, N. S., Sehgal, P., & Kukreja, M. (2025) · doi:10.25259/peak_19_2024 · Cited by 1
Examining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
Parikh, M., Pu, J., Shen, J., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag033
Peary, A., Vaidya, N., Jakicic, J., & Chao, A. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01426-y · Cited by 1
Ojo, P. O., Rotimi, D. E., Ezenabor, E. H., Akanji, M. A., & Adeyemı, O. S. (2026) · Discover Medicine · doi:10.1007/s44337-026-00686-6
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“The trial identified a dose-dependent increase in heart rate that peaked at 24 weeks and declined thereafter [38].”
InfluentialTreatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Why Do We Lose Bone During Weight Loss: Can It Be Prevented?
Shapses, S. A., & McGuire, B. D. (2026) · Current Osteoporosis Reports · doi:10.1007/s11914-026-00984-z · Cited by 1
“Moreover, a triple agonist medication with glucagon (i.e., retatrutide) resulted in up to 24% weight loss [96], and all GLP-1RA medications show significant health benefits. however, there is also some concern that GLP-1-RA-based therapy may contribute to excessive loss of lean mass [97, 98 ].”
Traitements médicamenteux par agonistes des récepteurs au GLP1 et obésité de l’adulte
Carette, C., Phan, A., & Czernichow, S. (2025) · Soins · doi:10.1016/j.soin.2025.05.020
江崎, 治. (2011) · Medical Entomology and Zoology
Pillai, A. A., Godin, S., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001310 · Cited by 1
Agonists and Antagonists of the Human GIP Receptor
Kizilkaya, H. S., Gasbjerg, L. S., Holst, J. J., & Rosenkilde, M. M. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch2
Adipositas: neue medikamentöse Therapien
Seufert, J. (2026) · Nervenheilkunde · doi:10.1055/a-2939-1909
“Die Effektivität ist hierbei inzwischen so hoch, dass diese medikamentösen Interventionen an die klinischen Effekte der Gewichtsreduktion von bariatrischen Operationen heranreichen.”
Demidova, T. Y., Расуловна, Б. А., & Омариевна, У. Ф. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-2-09 · Cited by 1
Singh, S., Kumar, R., Maharshi, V., Sinha, N., & Payra, S. (2026) · Indian Journal of Physiology and Pharmacology · doi:10.25259/ijpp_357_2025
Neue Medikamente zur Gewichtsreduktion – ethische Herausforderungen
Weidinger, I. S. (2026) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2748-4530
Kunicki, M., Katulska, Z., Wolert, W., & Kunicka, A. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109025
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Monnier, L., Schlienger, J.-L., & Colette, C. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.002
Vikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
Gomon, Y. М., Колбин, А. С., Spichakova, E. A., & Reznik, V. A. (2026) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-gcp-0022
Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome
Shahd, A., Bridges, N., & Goldstone, A. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1881392 · Cited by 1
“…also appear more effective than semaglutide for weight loss in non-PWS cohorts with overweight/obesity, but have yet to be used in PWS, including the triple GLP-1/GIP/glucagon analogue, retatrutide, and combined GLP-1/amylin analogues, such as semaglutide/cagrilintide and amycretin (137 – 140).”
Effective Anti-Obesity Drugs Make Losing Weight a Big Deal
Williams, S. C. P. (2023) · Engineering · doi:10.1016/j.eng.2023.11.005
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01154-4
Collazo–Clavell, M. L. (2025) · New England Journal of Medicine · doi:10.1056/nejme2510196
Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
Kwak, K. H., & Jung, C. H. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2803 · Cited by 1
“Triple agonists, exemplified by retatrutide, which targets GLP-1, GIP, and glucagon receptors simultaneously, have produced weight reductions exceeding 24% in phase 2 trials [11], signaling a potential shift toward pharmacological outcomes that parallel metabolic surgery.”
Krzystek, Ł., Buć, K., Buć, P., Mazurek, M., Józefczyk, J., Zieliński, K., Ganczar, K., Jurkowski, S., Rudzińska, M., & Zalewski, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4388
Identification of a Thermogenic Target in the Dorsal Raphe Nucleus for Weight ManagementPreprint
Moura‐Assis, A., Plucińska, K., Baleisyte, A., Meseguer, D., Chen, B., Pellegrino, K., Parolari, L., Shaked, J. T., Page, K. J., Barrows, D. W., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.650283
Wird es doch eine medikamentöse Therapie der OSA geben?
Fietze, I. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01902-8
Managing Obesity in Heart Failure Patients: Current Evidence and Strategies
Sharma, S., Giri, G. K., Desai, A., Ruiz, J., Gomez, V., & GOSWAMI, R. M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.016
Cautela, D., Valeria, I., Lombardi, A., Laratta, B., Castaldo, C. M., Balestrieri, M. L., Mocini, E., Migliaccio, S., & Tardito, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188057
“Among these compounds, retatrutide is currently the most advanced candidate in clinical development, with Phase 2 data demonstrating significant weight loss, improved glycemic control, and benefits across various cardiometabolic parameters, with an overall acceptable safety profile [26,27].”
InfluentialSex-specific metabolic responses to modulation of the glucagon-FGF21 axis in female micePreprint
Merrild, C., Johansen, V. B. I., Clemmensen, C., & Ranea‐Robles, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.09.647697
Nouvelles stratégies thérapeutiques dans l’arthrose
Siddiq, M. A. B., Oo, W. M., & Hunter, D. J. (2025) · Revue du Rhumatisme · doi:10.1016/j.rhum.2025.12.007
Retatrutide in type 2 diabetes mellitus and obesity: an overview
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2642415
“…23.5 kg, 8.1 kg/m 2 18.5 cm with 8 mg retatrutide with an initial dose of 2 mg; 25.9 kg, 9.0 kg/m 2 and 18.5 cm, with an initial dose of 4 mg and 26.2 kg; 9.1 kg/m 2 and 19.6 cm in the group treated with 12 mg reta-trutide vs. 1.8 kg, 0.7 kg/m 2 and 2.6 cm, respectively, in the control arm [20].”
InfluentialHyperuricemia, gout and obesity: should weight management be more of a focus in gout management?
Scilletta, S., Marco, M. D., Bosco, G., Barbagallo, F. D. G., Galeano, F., Tumminia, A., Milluzzo, A., Gaudio, A., Frittitta, L., Scicali, R., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104860
CagriSema: a novel dual-pathway approach to target obesity and its complications
Calero, I. V., Rodríguez, A., & Frühbeck, G. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.101
Glucagon Synthesis, Secretion, and Mechanisms of Action
Mohan, S., & Vella, A. V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00005-6
Novel Therapeutic Strategies for Obesity-Related Glomerulopathy
Liu, Y., Eirin, A., & Lerman, L. O. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01357-0 · Cited by 2
“Retatrutide, a triple-agonist of GIP, GLP-1, and glucagon receptors, induces substantial weight-loss after 48 weeks in adults with obesity [57].”
Hoekx, C. A., Brinkman, L. B. D., van Eenige, R., Kooijman, S., Muskiet, M. H. A., Jazet, I. M., Martínez‐Téllez, B., Rensen, P. C. N., & Boon, M. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70704
GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways
Lindquist, P., Dijkhof, L. R. H., Drzazga, A. K., Sabatier, P., Stępniewski, T. M., Granlund, L., Lechner, M. Y., Zhong, Y., Gasbjerg, L. S., Hartmann, B., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.06.003
Ekinci, E. I., Maldonado, S. G., Unseld, A., Arrubla, J., Hennige, A. M., & Schoelch, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70861
Current trends in pharmacotherapy of overweight and obesity
Ürgeová, A., & Kozárová, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.099
The ‘Slow Burn’ Phenotype: How Relative Caloric Intake Reveals Hidden Cardiovascular Risk Beyond BMI
Cho, Y. K., Jhee, J. H., Jhee, J. H., & Park, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71192
GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Pawar, M., Patil, C. S., Fakir, J. S., Pagar, D. S., & Mahajan, S. K. (2025) · BioMed Target Journal · doi:10.59786/bmtj.322 · Cited by 1
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156026
“GIP, secreted from duodenal K-cells, also potentiates insulin secretion; co-targeting GIP and GLP-1 receptors (as in tirzepatide) yields metabolic effects exceeding selective GLP-1 agonism [12,13].”
Du, Y., Liu, T., Li, H.-L., Luo, Q., Guo, X.-Y., Wang, J., Wang, X., Zhou, Y.-M., Pan, Y., Yu, L., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00261
Self-citationRecent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Challenges and Novelties in the Treatment of Obesity in Adults. A review
Kuczapska, K., Kurowski, M., Gliwa, A., Ryglewicz, M., Fabian, D., Leszczyńska-Knaga, E., Jakubczyk, N., Rutkowska-Kawalec, W., Moczydłowski, P., & Michalczuk, K. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.77.57095
Kennedy, C., Conroy, L., Millar, B., & de Gaetano, M. (2025) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2025.187
Adipositas und Herz: neue Medikamente und neue Strategien für Kardiologen
Hollstein, T. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2606-7020
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108365 · Cited by 1
Angelopoulos, A., Fragoulis, G., Papagoras, C., & Daoussis, D. (2026) · Rheumatology International · doi:10.1007/s00296-026-06258-2 · Cited by 1
Les meilleures études en 2023 adaptées aux soins primaires
Thomas, B. S., Perry, D., Moe, S. S., et al. (2024) · Canadian Family Physician · doi:10.46747/cfp.7004e47
Simental‐Mendía, L. E., Barragán‐Zuñiga, L. J., & Reyes-Avitia, V. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00812-6
Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller
Nauck, M. A. (2023) · Deutsches Ärzteblatt · doi:10.3238/persdia.2023.11.03.01
Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure
Nicze, M., Borówka, M., Dec, A., Bułdak, Ł., Bołdys, A., & Okopień, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062539 · Cited by 7
Mansouri, E. S., de Queiroga, F. F., Barbosa, L., Azevedo, A. K., Donaldy, W., Mirbolouk, M. J., Freire, C. V. S., Rivera, A., Félix, I. F., Abreu, M., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044249 · Cited by 1
Konservative Adipositastherapie
Kretschmer, A. C., Arjune, S., & Hanßen, R. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01160-6
Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review
Fujioka, K. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70172
“71 Both treatments may be available by 2027.”
Recent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Choi, H. S., & Bae, E. H. (2025) · Korean Journal of Medicine · doi:10.3904/kjm.2025.100.2.61
GLP-1-based multipharmacology: Biased signaling as a determinant of therapeutic efficacy
Li, W., Yan, J., Zhao, F., & Yang, D. (2026) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2026.07.001
Beyond Percentage of Weight Lost — Protecting Participants in Obesity Trials
Schmitz, S. H. (2026) · New England Journal of Medicine · doi:10.1056/nejmp2609407
Emerging Therapeutic Agents for Obesity and Future Perspectives
Otoda, T. (2025) · Journal of Nihon University Medical Association · doi:10.4264/numa.84.4_185
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.